Profile and behavior of antiviral drugs in aquatic environments of the Pearl River Delta, China

Science of the Total Environment

Volumn 466-467, Issue , 2014, Pages 755-761

  Peng, Xianzhi ^a   Wang, Chunwei ^a,b   Zhang, Kun ^a,b   Wang, Zhifang ^a,b   Huang, Qiuxin ^a,b   Yu, Yiyi ^a,b   Ou, Weihui ^a,b  

^a GUANGZHOU INSTITUTE OF GEOCHEMISTRY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Acyclovir; Antiviral pharmaceuticals; Groundwater; Surface water; The Pearl River Delta; Wastewater

Indexed keywords

ACYCLOVIR; AEROBIC BIODEGRADATION; AQUATIC ENVIRONMENTS; MAXIMUM CONCENTRATIONS; MUNICIPAL LANDFILLS; OSELTAMIVIR CARBOXYLATE; PEARL RIVER DELTA; SOURCE IDENTIFICATION;

ANTIVIRAL AGENTS; BIODEGRADATION; CARBOXYLATION; GROUNDWATER; LAND FILL; RESERVOIRS (WATER); RIVERS; SURFACE WATERS; VIRUSES; WASTEWATER; WASTEWATER TREATMENT;

EFFLUENTS;

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ACICLOVIR; ANTIVIRUS AGENT; GANCICLOVIR; OSELTAMIVIR; RIBAVIRIN; RIVER WATER; STAVUDINE; WELL WATER; ZIDOVUDINE; FRESH WATER; GROUND WATER; WASTE WATER; WATER POLLUTANT;

AQUATIC ENVIRONMENT; DRUG; GROUNDWATER; SURFACE WATER; WASTEWATER;

AQUATIC ENVIRONMENT; ARTICLE; BIODEGRADATION; CHINA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DILUTION; EFFLUENT; LANDFILL; LANDFILL LEACHATE; POLLUTION TRANSPORT; PRECIPITATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RIVER; SEASONAL VARIATION; WASTE WATER MANAGEMENT; WATER ANALYSIS; WATER POLLUTION; WATER SAMPLING; WATER SUPPLY; WINTER; ANALYSIS; ELECTROSPRAY MASS SPECTROMETRY; ENVIRONMENTAL MONITORING; LIQUID CHROMATOGRAPHY; SEASON; TANDEM MASS SPECTROMETRY; WASTE DISPOSAL FACILITY; WASTE WATER; WATER POLLUTANT;

CHINA; GUANGDONG; ZHUJIANG DELTA;

ANTIVIRAL AGENTS; CHINA; CHROMATOGRAPHY, LIQUID; ENVIRONMENTAL MONITORING; FRESH WATER; GROUNDWATER; SEASONS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; WASTE DISPOSAL FACILITIES; WASTE WATER; WATER POLLUTANTS, CHEMICAL;

EID: 84882963529     PISSN: 00489697     EISSN: 18791026     Source Type: Journal    
DOI: 10.1016/j.scitotenv.2013.07.062     Document Type: Article

References (48)

1. Accinelli C., Caracciolo A.B., Grenni P. Degradation of the antiviral drug oseltamivir carboxylate in surface water samples. Int J Environ Analy Chem 2007, 87(8):579-587.
2. Accinelli C., Saccà M.L., Batisson I., Fick J., Mencarelli M., Grabic R. Removal of oseltamivir (Tamiflu) and other selected pharmaceuticals from wastewater using a granular bioplastic formulation entrapping propagules of Phanerochaete chrysosporium. Chemosphere 2010, 81:436-443.
3. Accinelli C., Sacca M.L., Fick J., Mencarelli M., Lindberg R., Olsen B. Dissipation and removal of oseltamivir (Tamiflu) in different aquatic environments. Chemosphere 2010, 79(8):891-897.
4. Azuma T., Nakada N., Yamashita N., Tanaka H. Synchronous dynamics of observed and predicted values of anti-influenza drugs in environmental waters during a seasonal influenza outbreak. Environ Sci Technol 2012, 46(23):12873-12881.
5. Bartels P., von Tumpling W. The environmental fate of the antiviral drug oseltamivir carboxylate in different waters. Sci Total Environ 2008, 405(1-3):215-225.
6. Caracciolo A.B., Grenni P., Sacca M.L. Effect of the antiviral drug oseltamivir (Tamiflu) on the bacterial community structure of a surface water ecosystem analyzed using fluorescence in situ hybridization. Bullet Environ Contam Toxicol 2010, 85:443-446.
7. Chinese Center for Disease Control, Prevention [Accessed on April 16, 2013]. http://www.pandemicflu.ac.cn/.
8. Choi K., Kim Y., Park J., Park C.K., Kim M., Kim H.S., et al. Seasonal variations of several pharmaceutical residues in surface water and sewage treatment plants of Han River, Korea. Sci Total Environ 2008, 405:120-128.
9. Concalves C., Pere S., Osorio V., Petrovic M., Alpendurada M.F., Barcelo D. Photofate of oseltamivir (Tamiflu) and oseltamivir carboxylate under natural and simulated solar irradiation: kinetics, identification of the transformation products, and environmental occurrence. Environ Sci Technol 2011, 45:4307-4314.
10. De Clercq E., Field H.J. Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol 2006, 147(1):1-11.
11. Ellis J.B. Antiviral pandemic risk assessment for urban receiving waters. Water Sci Technol 2010, 879-884.
12. Escher B.I., Bramaz N., Lienert J., Neuwoehner J., Straub J.O. Mixture toxicity of antiviral drug Tamiflu (oseltamivir ethylester) and its active metabolite oseltamivir acid. Aquat Toxicol 2010, 96:194-202.
13. Fick J., Lindberg R.H., Tysklind M., Haemig P.D., Waldenstrom J., Wallensten A., et al. Antiviral oseltamivir is not removed or degraded in normal sewage water treatment: implications for development of resistance by influenza A virus. PLoS One 2007, 2:e986.
14. Ghosh G.C., Okuda T., Yamashita N., Tanaka H. Occurrence and elimination of antibiotics at four sewage treatment plants in Japan and their effects on bacterial ammonia oxidation. Water Sci Technol 2009, 59(4):779-786.
15. Ghosh G.C., Nakada N., Yamashita N., Tanaka H. Occurrence and fate of oseltamivir carboxylate (Tamiflu) and amantadine in sewage treatment plants. Chemosphere 2010, 81(1):13-17.
16. Ghosh G.C., Nakada N., Yamashita N., Tanaka H. Oseltamivir carboxylate, the active metabolite of oseltamivir phosphate (Tamiflu), detected in sewage discharge and river water in Japan. Environ Health Perspect 2010, 118(1):103-107.
17. Goncalves C., Perez S., Osorio V., Petrovic M., Alpendurada M.F., Barcelo D. Photofate of oseltamivir (Tamiflu) and oseltamivir carboxylate under natural and simulated solar irradiation: kinetics, identification of the transformation products, and environmental occurrence. Environ Sci Technol 2011, 45(10):4307-4314.
18. Guangzhou Environmental Protection Bureau [Accessed on August 30, 2012]. http://www.gzepb.gov.cn/.
19. Guangzhou Statistics [Accessed on March 22, 2013]. http://data.gzstats.gov.cn/gzStat1/chaxun/njsj.jsp.
20. Hauser A., Mugenyi K., Kabasinguzi R., Kuecherer C., Harms G., Kunz A. Emergence and persistence of minor drug-resistant HIV-1 variants in Ugandan women after nevirapine single-dose prophylaxis. PLoS One 2011, 6:e20357.
21. Huang Q.X., Yu Y.Y., Tang C.M., Peng X.Z. Determination of commonly used azole antifungals in various waters and sewage sludge using ultra-high performance liquid chromatography-tandem mass spectrometry. J Chromatogr A 2010, 1217(21):3481-3488.
22. Hutchinson T.H., Beesley A., Frickers P.E., Readman J.W., Shaw J.P., Straub J.O. Extending the environmental risk assessment for oseltamivir (Tamiflu®) under pandemic use conditions to the coastal marine compartment. Environ Int 2009, 35:931-936.
23. Kim S.J., Kim K., Do Y.R., Bae S.H., Yang D.H., Lee J.J. Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study. Jpn J Clin Oncol 2011, 41(3):353-357.
24. Kiso M., Mitamura K., Sakai-Tagawa Y., Shiraishi K., Kawakami C., Kimura K., et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004, 364(9436):759-765.
25. Kolpin D.W., Skopec M., Meyer M.T., Furlong E.T., Zaugg S.D. Urban contribution of pharmaceuticals and other organic wastewater contaminants to streams during differing flow conditions. Sci Total Environ 2004, 328:119-130.
26. Koreje K.O., Demeestere K., De Wispelaere P., Vergeynst L., Dewulf J., Van Langenhove H. From multi-residue screening to target analysis of pharmaceuticals in water: development of a new approach based on magnetic sector mass spectrometry and application in the Nairobi River basin, Kenya. Sci Total Environ 2012, 437:153-164.
27. Leknes H., Sturtzel I.E., Dye C. Environmental release of oseltamivir from a Norwegian sewage treatment plant during the 2009 influenza A (H1N1) pandemic. Sci Total Environ 2012, 414:632-638.
28. Mestankova H., Schirmer K., Escher B.I., von Gunten U., Canonica S. Removal of the antiviral agent oseltamivir and its biological activity by oxidative processes. Environ Pollut 2012, 161:30-35.
29. Olsen B., Munster V.J., Wallensten A., Waldenstrom J., Osterhaus A.D.M.E., Fouchier R.A.M. Global patterns of influenza A virus in wild birds. Science 2006, 312(5772):384-388.
30. Ort C., Lawrence M.G., Reungoat J., Mueller J.F. Sampling for PPCPs in wastewater systems: comparison of different sampling modes and optimization strategies. Environ Sci Technol 2010, 44:6289-6296.
31. Ort C., Lawrence M.G., Rieckermann J., Adriano J. Sampling for pharmaceuticals and personal care products (PPCPs) and illicit drugs in wastewater systems: are your conclusions valid? A critical review. Environ Sci Technol 2010, 44:6024-6035.
32. Prasse C., Schlusener M.P., Schulz R., Ternes T.A. Antiviral drugs in wastewater and surface waters: a new pharmaceutical class of environmental relevance?. Environ Sci Technol 2010, 44:1728-1735.
33. Prasse C., Wagner M., Schulz R., Ternes T.A. Biotransformation of the antiviral drugs acyclovir and penciclovir in activated sludge treatment. Environ Sci Technol 2011, 45(7):2761-2769.
34. Prasse C., Wagner M., Schulz R., Ternes T.A. Oxidation of the antiviral drug acyclovir and its biodegradation product carboxy-acyclovir with ozone: kinetics and identification of oxidation products. Environ Sci Technol 2012, 46:2169-2178.
35. Radke M., Lauwigi C., Heinkele G., Murdter T.E., Letzel M. Fate of the antibiotic sulfamethoxazole and its two major human metabolites in a water sediment test. Environ Sci Technol 2009, 43:3135-3141.
36. Renner R. Tamiflu survives sewage treatment. Environ Sci Technol 2007, 41(22):7591.
37. Sacca M.L., Accinelli C., Fick J., Lindberg R., Olsen B. Environmental fate of the antiviral drug Tamiflu in two aquatic environments. Chemosphere 2009, 75:28-33.
38. Sanderson H., Johnson D.J., Reitsma T., Brain R.A., Wilson C.J., Solomon K.R. Ranking and prioritization of environmental risks of pharmaceuticals in surface waters. Regul Toxicol Pharmacol 2004, 39(2):158-183.
39. Singer A.C., Nunn M.A., Gould E.A., Johnson A.C. Potential risks associated with the proposed widespread use of Tamiflu. Environ Health Perspect 2007, 115(1):102-106.
40. Singer A.C., Johnson A.C., Anderson P.D., Snyder S.A. Reassessing the risks of Tamiflu use during a pandemic to the Lower Colorado River. Environ Health Perspect 2008, 116(7):A285-A286.
41. Singer A.C., Colizza V., Schmitt H., Andrews J., Balcan D., Huang W.E., et al. Assessing the ecotoxicologic hazards of a pandemic influenza medical response. Environ Health Perspect 2011, 119(8):1084-1090.
42. Slater F.R., Singer A.C., Turner S., Barr J.J., Bond P.L. Pandemic pharmaceutical dosing effects on wastewater treatment: no adaptation of activated sludge bacteria to degrade the antiviral drug Oseltamivir (Tamiflu®) and loss of nutrient removal performance. FEMS Microbiol Lett 2011, 315(1):17-22.
43. Soderstrom H., Jarhult J.D., Olsen B., Lindberg R.H., Tanaka H., Fick J. Detection of the antiviral drug oseltamivir in aquatic environments. PLoS One 2009, 4:e6064.
44. Straub J.O. An environmental risk assessment for oseltamivir (Tamiflu®) for sewage works and surface waters under seasonal-influenza- and pandemic-use conditions. Ecotoxicol Environ Saf 2009, 72(6):1625-1634.
45. Takanami R., Ozaki H., Giri Rabindra R., Taniguchi S., Hayashi S. Detection of antiviral drugs oseltamivir phosphate and oseltamivir carboxylate in Neya River, Osaka, Japan. J Water Environ Technol 2010, 8(4):363-372.
46. Vieno N.M., Tuhkanen T., Kronberg L. Seasonal variation in the occurrence of pharmaceuticals in effluents from a sewage treatment plant and in the recipient water. Environ Sci Technol 2005, 39:8220-8226.
47. Wang Y. Analysis of dosage and requirements for antiviral drugs. China Med Phar 2012, 2:176-178. [in Chinese].
48. Yu Y.Y., Huang Q.X., Wang Z.F., Zhang K., Tang C.M., Cui J.L., et al. Occurrence and behavior of pharmaceuticals, steroid hormones, and endocrine-disrupting personal care products in wastewater and the recipient river water of the Pearl River Delta, South China. J Environ Monit 2011, 13:871-878.